Unresectable Hepatocellular
Original Article Transhepatic arterial chemoembolizations with lobaplatin-eluting microspheres for the treatment of unresectable hepatocellular carcinoma
... treating unresectable hepatocellular carcinoma ...with unresectable hepatocellular carcinoma and preserved liver function, who were treated with TACE using lobaplatin-eluting microspheres ...
8
<p>Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma</p>
... Transarterial chemoembolization (TACE) is most commonly recommended as the fi rst-line treatment for unresectable hepatocellular carcinoma (HCC) 1,2 and also as the standard treatment for intermediate-stage ...
7
Original Article Prognostic value of systemic inflammation response SIR parameters in unresectable hepatocellular carcinoma
... Abstract: Hepatocellular carcinoma (HCC) is one of the most common malignancies, with increasing incidence and dismal ...in unresectable hepatocellular carcinoma ...
10
<p>Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date</p>
... Abstract: During the last 10 years, the multikinase inhibitor sorafenib has emerged as the only systemic treatment for unresectable hepatocellular carcinoma (HCC). More recently, data from the Phase III ...
9
Prognostic role of ABO blood group in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization
... with unresectable HCC met at least one of the following criteria: patient’s refusal resec- tion, multiple lesions of the liver, and the presence of invasion of major blood ...282 unresectable HCC patients ...
8
Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
... Several clinical trials have evaluated survival outcomes in HCC patients who received combination therapy, but the findings differed greatly among studies and thus re- main debatable. It remains a pending issue as to ...
13
Transarterial chemoembolization using iodized oil for unresectable hepatocellular carcinoma: perspective from multistep hepatocarcinogenesis
... Figure 6 Schematic presentation of the relationship between the distribution of Lipidol emulsion/suspension and histological grades of hepatocellular carcinomas. Notes: (A) well or moderately differentiated ...
6
Effects of Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma Using a Combination of Platinum Agents (Cisplatin plus Miriplatin): A Retrospective Comparison with Cisplatin Monotherapy
... Hepatocellular carcinoma (HCC) is one of the most frequent malignant diseases globally [1]. In Japan, more than 30,000 people die from HCC each year [2]. Curative therapies, including surgical resection, liver ...
14
Yttrium-90 radioembolization of unresectable hepatocellular carcinoma – a single center experience
... RE at our institution were progressive disease (PD) under a TACE treatment regime, contraindications for TACE/ chemotherapy (eg, portal vein thrombosis/invasion, cardiac comorbidities) as well as impaired hemostasis (as ...
13
Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials
... Our meta-analysis reveals that TARE and TACE have similar effects in unresectable HCC patients in terms of overall survival, disease control rate, transplantation rate, and progression rate. It is very unlikely ...
7
Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
... the intent of identifying optimal combination therapies to improve survival outcomes in patients with advanced unre- sectable HCC. All patients in our retrospective analysis had unresectable HCC and a Child–Pugh ...
7
Role of Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma.
... 29 had Stage III lesions. Adriamycin or cisplatin infusion was carried out, followed by chemoembolization therapy of tumor vessels using mixture of ethiodized oil or iophendylate and mitomycin C. Finally, gelatin sponge ...
73
Mechanism related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
... Hepatocellular carcinomas (HCCs) overexpress several angiogenic proteins, including vascular endothelial growth factor-A (VEGF-A) [1-3], VEGF-D [4], and pla- telet-derived endothelial growth factor (PDGF) [2], as ...
14
Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib
... The multi-kinase inhibitor sorafenib is now used as standard therapy for advanced hepatocellular carcinoma (HCC). Predictive biomarkers of response to sorafenib are thus necessary. The purpose of this study was to ...
9
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
... We searched PubMed for articles published between Jan 1, 2000, and the start of the TACE 2 trial on Nov 1, 2010, using the search terms, “hepatocellular carcinoma” and “sorafenib”. This search yielded two ...
11
Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study
... Background: Transarterial chemoembolization (TACE) is recommended as the standard care for unresectable hepa‑ tocellular carcinoma (HCC) at Barcelona Clinic Liver Cancer (BCLC) stage A–B. However, the efficacy of ...
8
Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis
... (i) unresectable HCC with macroscopic hepatic vascular in- vasion; (ii) C-P class A or B hepatic function; (iii) an ECOG performance status of 0–2; (iv) no refractory asci- tes; and (v) no previous radiation ...
7
Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma
... advanced, unresectable HCC as a sec- ond- or third-line treatment, future trials may select patients most likely to benefit, such as using pretreatment octreotide image scanning and testing available tumor samples ...
7
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
... trial in 602 patients with advanced HCC demonstrates an improvement in the median overall survival (10.7 months) in the sorafenib group versus the placebo group (7.9 months).[6] Multimodal therapeutic approaches using ...
10
Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria
... RFA treatment following TACE has some advantages over TACE alone. Embolization during the TACE pro- cedure can block arterial flow, which may reduce heat-sink effects during RFA thus increasing the volume of the zone of ...
7